|
EP2325185A1
|
|
Plk inhibitor
|
|
EP2112152A1
|
|
Dihydropteridinones as Plk Inhibitors
|
|
EP1905439A1
|
|
Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
|
|
EP1905437A1
|
|
Treatment of pain using satraplatin
|
|
EP2019101A1
|
|
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
|
WO2006089874A1
|
|
Benzo[2,3]azepino[4,5-b]indol-6-ones
|
|
CA2593718A1
|
|
Napthyridine compounds as rock inhibitors
|
|
EP1792622A1
|
|
Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
|
|
EP1786781A2
|
|
Pyrimidine derivatives
|
|
EP1789393A2
|
|
Pyridinylamines
|
|
AU2005275205A1
|
|
Variable-dose packaging system
|
|
WO2005120479A1
|
|
Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
|
|
WO2005105097A2
|
|
Pyridopyrimidines for treating inflammatory and other diseases
|
|
EP1700598A1
|
|
Anti-proliferative combination therapy comprising satraplatin or JM118 and docetaxel
|
|
EP1967189A1
|
|
Methods for treating resistant or refractory tumors
|
|
EP2096107A1
|
|
Derivatives of squaric acid with anti-proliferative activity
|
|
EP1694670A1
|
|
Pyrazine derivatives as effective compounds against infectious diseases
|
|
EP1673346A1
|
|
Quinazoline derivatives for the treatment of herpesviral infections
|
|
AU2004270394A1
|
|
Heterobicyclic compounds as pharmaceutically active agents
|
|
CA2538141A1
|
|
Therapeutic human anti-mhc class ii antibodies and their uses
|
